Citius Oncology (NASDAQ:CTOR) Upgraded at Wall Street Zen

Key Points

• Citius Oncology (NASDAQ: CTOR) has been upgraded to a "hold" rating by Wall Street Zen, following similar downgrades from other analysts such as Maxim Group and Citigroup.
• The company reported a missing EPS of ($0.11) in its latest quarterly earnings, falling short of analysts' estimates of ($0.09).
• A hedge fund, Citadel Advisors LLC, recently purchased 22,699 shares of Citius Oncology, indicating significant institutional interest as 70.52% of the stock is owned by institutional investors.

Wall Street Zen upgraded shares of Citius Oncology (NASDAQ:CTOR - Free Report) to a hold rating in a research report sent to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Citigroup downgraded shares of Citius Oncology to a "hold" rating in a report on Friday, May 23rd. Maxim Group downgraded shares of Citius Oncology from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd.

Citius Oncology Stock Up 10.2%

CTOR traded up $0.19 during midday trading on Friday, reaching $2.06. 1,618,819 shares of the company's stock were exchanged, compared to its average volume of 2,507,610. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.05 and a current ratio of 0.36. The business's 50-day moving average price is $2.18 and its 200 day moving average price is $1.37. Citius Oncology has a 1-year low of $0.55 and a 1-year high of $49.00.

Citius Oncology (NASDAQ:CTOR - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02).

Institutional Investors Weigh In On Citius Oncology

A hedge fund recently bought a new stake in Citius Oncology stock. Citadel Advisors LLC bought a new stake in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,699 shares of the company's stock, valued at approximately $26,000. 70.52% of the stock is owned by institutional investors and hedge funds.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.